License to AstraZeneca. Subject to the terms and conditions of this Agreement, Xxxxxxxxx hereby grants to AstraZeneca, effective on the Effective Date, (a) a royalty-bearing, co-exclusive license, with the right to sublicense as set forth in Section 2.5, under the Xxxxxxxxx Technology and Xxxxxxxxx’x interest in the Joint Technology, to Develop the Collaboration Compound and Collaboration Products in the Field in the Territory in accordance with the terms of this Agreement and (b) a royalty-bearing, exclusive (even as to Xxxxxxxxx) license, with the right to sublicense as set forth in Section 2.5, under the Xxxxxxxxx Technology and Xxxxxxxxx’x interest in the Joint Technology, to Manufacture and Commercialize the Collaboration Products in the Field in the Territory.
License to AstraZeneca. Subject to the terms and conditions of this Agreement, FibroGen China hereby grants AstraZeneca a co-exclusive (with FibroGen Cayman, who retains a licensable right to develop, use, sell, offer for sale, import and Commercialize Products in the Field in the Territory), royalty-bearing, sublicensable (solely as permitted in accordance with Section 7.3) license under the FibroGen China Technology and the Marks to Develop (solely in accordance with the applicable Development Plan), use, sell, offer for sale, import and Commercialize, but not Manufacture, Products in the Field in the Territory. With respect to any Product hereunder, notwithstanding the foregoing, AstraZeneca shall (a) not exercise any of the co-exclusive rights to Develop granted hereunder until FibroGen WFOE has sole ownership of and is the sole named party for the regulatory licenses in the Territory, which shall include without limitation the (i) New Drug License, (ii) Product Approval Code, (iii) Manufacturing License, and (iv) GMP License, and for such licenses any other necessary, related or successor licenses, and (b) take all actions and execute all documents reasonably necessary to ensure that FibroGen WFOE shall solely hold such licenses. FibroGen shall promptly notify AstraZeneca upon the issuance of such licenses.
License to AstraZeneca. (a) Subject to the terms and conditions of this Agreement, BIND hereby grants to AstraZeneca and its Affiliates an exclusive (including with regard to BIND and its Affiliates) worldwide, royalty-bearing license in the Field under the Exclusive Licensed Technology to research, develop (including to conduct Clinical Development), Manufacture, Commercialize, import, use, sell, offer for sale and otherwise exploit a Product Candidate alone and in the Product.
License to AstraZeneca. Subject to the terms and conditions of this Agreement, Ironwood hereby grants to AstraZeneca, a perpetual (except as otherwise provided in Section 8), exclusive, nontransferable (except as set forth in Section 10.9) license, with the right to grant sublicenses as described in Section 2.6 and, subject only to the rights reserved to Ironwood to the extent necessary to perform its obligations or exercise its rights hereunder under the Ironwood Technology and Ironwood’s interest in the Joint Technology and Development Data to Develop the Licensed Compound and Products pursuant to the Development Plans and to Commercialize Products pursuant to the Commercialization Plans in each case, in the Field in the Territory and, subject to Section 3.3, to make or have made the Licensed Compound or Products anywhere in the world for Development or Commercialization in the Field in the Territory. Notwithstanding the foregoing, Ironwood reserves the right under the Ironwood Technology and Ironwood’s interest in the Joint Technology and the Development Data to (a) subject to Section 3.2.5(c), develop and manufacture the Licensed Compound and Products inside or outside of the Territory in support of development or commercialization of the Licensed Compound and Products outside of the Territory, (b) Develop and Manufacture the Licensed Compound and Products in the Territory and Commercialize the Products in the Territory in the Field pursuant to Section 3.5.4 upon exercise of Ironwood’s rights thereunder, (c) develop and commercialize the Licensed Compound and Products in the Territory outside of the Field, and (d) commercialize the Licensed Compound and Products outside of the Territory, in each case ((a) through (d)) in accordance with any applicable terms of this Agreement. Unless and until specified in Section 5.3, [**]. The Parties acknowledge that the Development Plan currently contemplates and may in the future contemplate certain Development activities for the Territory that may occur outside the Territory and agree that such Development activities for such purpose shall be considered in the Territory for purposes of this Agreement.
License to AstraZeneca. The Institution and the Principal Investigator agree that, if either publishes the results of the Multi-Center Study or the Study, AstraZeneca is hereby granted an irrevocable, royalty-free license to make and distribute copies of such publication under any copyright privileges that the Institution and the Principal Investigator may have. AstraZeneca also shall have the right to publish independently the results of the Multi-Center Study and the Study. The Institution and the Principal Investigator shall, in any agreement with a journal or other publisher to publish the results of the Multi-Center Study or the Study, use reasonable efforts to reserve expressly all copyright rights necessary to grant AstraZeneca the license and rights contained herein.
License to AstraZeneca
